A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ADENOASSOCIATED VIRUS SEROTYPE 8 (AAV8)-MEDIATED GENE TRANSFER OF HUMAN ORNITHINE TRANSCARBAMYLASE (OTC) IN PATIENTS WITH LATE-ONSET OTC DEFICIENCY
- Registry ID
- DTX301-CL301
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ULTRAGENYX PHARMACEUTICAL INC
- Start date
- 2025-09-12
- Last update
- 2022-08-03
Conditions
- ORNITHINE TRANSCARBAMYLASE DEFICIENCY
View on source registry